Publisher
Springer Berlin Heidelberg
Reference31 articles.
1. Bon GG, Kenemans P, Van Kamp GJ, Yedema CA, Hilgers J (1990) Review on the clinical value of polymorphic epithelial mucin tumor markers for the management of carcinoma patients. J Nucl Med Allied Sci 34 [Suppl]: 151–162
2. Durie BGM, Stock-Novack D, Salmon SE, Finley P, Beckford J, Crowley J, Coltman CA (1990) Prognostic value of pretreatment serum β2-microglobulin in myeloma: a southwest oncology group study. Blood 75:823–830
3. Ebert W, Leichtweis B, Schapöhler B, Muley Th (1993) The new tumor marker CYFRA is superior to SCC antigen and CEA in the primary diagnosis of lung cancer. Tumordiagn Ther 14:91–99
4. Fletcher RH (1986) Carcinoembryonic antigen. Ann Intern Med 104:66–73
5. Hallek M, Wanders L, Strohmeyer S, Emmerich B (1992) Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin’s lymphoma and a broad range of potential clinical applications. Ann Hematol 65:1–5